Breast cancer organoids mimic disease heterogeneity, allow high-throughput drug screening and show correlation with clinical response

Breast cancer (BC) is a highly heterogeneous disease; therefore, it is urgent to identify an ex vivo model that accurately mimics the heterogeneity. Patient-derived organoids (PDOs) represent an ideal preclinical model for human tumors, thus facilitating the translation of basic cancer research to clinical practice by assessing drug responses in a personalized fashion.